Guru Ownership Trend
Guru Analysis for Nektar Therapeutics (NKTR)
Nektar Therapeutics (NKTR), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $4.67 M.
Top institutional holders include Renaissance Technologies (RenTech) and Paul Tudor Jones.
Institutional sentiment is currently Slightly Bearish. This is evidenced by a $43.31 M net outflow during the quarter.
Recent activity highlights Paul Tudor Jones who opened a new position. Conversely, Steven Cohen reduced exposure by 96.9%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Nektar Therapeutics (NKTR)
Major holders include Renaissance Technologies (RenTech) ($3.01 M), Paul Tudor Jones ($1.08 M), Steven Cohen ($961,540). According to the latest reported data, 3 tracked investment managers collectively hold approximately 70,129 shares.
According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $43.31 M, with 1 managers increasing positions and 3 managers reducing holdings.
During the most recent reporting period, 2 managers trimmed their positions, while 1 fully exited NKTR. The total reported sell value was $44.39 M.
Yes, 1 managers opened new positions in NKTR, and 0 increased their existing holdings. The total reported buy value was $1.08 M.